Arbutus Biopharma (ABUS) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Arbutus Biopharma (ABUS) overview

Arbutus Biopharma (ABUS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 14.1m and operating profit of USD -38.2m; the year-end share price was 4.81 USD and market capitalisation was USD 926m. Arbutus Biopharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arbutus Biopharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 76.6mFY 2025
Share price4.81 USDFY 2025 year end
RevenueUSD 14.1mFY 2025
Operating profitUSD -38.2mFY 2025
Net earningsUSD -33.5mFY 2025
Market capitalisationUSD 926mFY 2025 year end

About Arbutus Biopharma

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. It is developing imdusiran, a subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B. The company also holds intellectual property related to lipid nanoparticle technology and pursues licensing and patent litigation activities concerning its use in mRNA vaccines.

Generate the Arbutus Biopharma report

Arbutus Biopharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Arbutus Biopharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Arbutus Biopharma

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.